Moderna Reports Third-Quarter Revenue of $1.31B and EPS of $0.38
Third-quarter revenue rose 29% year over year, and Moderna returned to net income from a year-earlier loss. Higher international COVID vaccine sales more than offset generally consistent U.S. product sales.
Moderna's third-quarter revenue rose 29% year over year, as higher COVID vaccine sales in international markets—driven by deliveries under long-term government partnerships—more than offset generally consistent U.S. product sales. The company returned to net income from a year-earlier loss, while l…